Victor Sandor

8.0k total citations · 2 hit papers
35 papers, 3.2k citations indexed

About

Victor Sandor is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Victor Sandor has authored 35 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 16 papers in Genetics and 14 papers in Hematology. Recurrent topics in Victor Sandor's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). Victor Sandor is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Acute Myeloid Leukemia Research (6 papers). Victor Sandor collaborates with scholars based in United States, Canada and Italy. Victor Sandor's co-authors include Susan E. Bates, Robert W. Robey, Susan Bakke, Richard Piekarz, Michael D. Pickard, Paolo A. Ascierto, Reinhard Dummer, Caroline Robert, Mario Mandalà and Dirk Schadendorf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Victor Sandor

35 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

2018 675 citations Reinhard Dummer, Paolo A. Ascierto et al. The Lancet Oncology profile →
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

2018 392 citations Reinhard Dummer, Paolo A. Ascierto et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Victor Sandor

Since Specialization

Citations

This map shows the geographic impact of Victor Sandor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor Sandor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor Sandor more than expected).

Fields of papers citing papers by Victor Sandor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor Sandor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor Sandor. The network helps show where Victor Sandor may publish in the future.

Co-authorship network of co-authors of Victor Sandor

This figure shows the co-authorship network connecting the top 25 collaborators of Victor Sandor. A scholar is included among the top collaborators of Victor Sandor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor Sandor. Victor Sandor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors 2020 ·Clinical Cancer Research ·Ryan J. Sullivan, Jeffrey S. Weber, Sapna P. Patel, Reinhard Dummer, Matteo S. Carlino, Daniel Shao-Weng Tan, Célèste Lebbé, Salvatore Siena, Élena Elez, Lance Wollenberg, Michael D. Pickard, Victor Sandor, Paolo A. Ascierto	30
2	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial breakdown → 2018 ·The Lancet Oncology ·Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty	392
3	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial breakdown → 2018 ·The Lancet Oncology ·Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty	675
4	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). 2016 ·Journal of Clinical Oncology ·Josep Tabernero, Robin M.J.M. van Geel, Tormod Kyrre Guren, Rona Yaeger, Anna Spreafico, Jason E. Faris, Takayuki Yoshino, Yasuhide Yamada, Tae Won Kim, Johanna C. Bendell, Martin Schüler, Heinz‐Josef Lenz, Ferry A.L.M. Eskens, Jayesh Desai, Howard S. Höchster, Emin Avşar, Tim Demuth, Victor Sandor, Élena Elez, Jan H.M. Schellens	82
5	Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed 2015 ·Journal of Clinical Oncology ·Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner, Johanna C. Bendell, J. Thaddeus Beck, (unknown), John Nemunaitis, Philip J. Stella, J. Marc Pipas, Zev A. Wainberg, Robert Manges, William M. Garrett, Deborah Hunter, Jason Clark, Lance Leopold, Victor Sandor, Richard S. Levy	237
6	Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Ruben A. Mesa, Srđan Verstovšek, Vikas Gupta, John Mascarenhas, Ehab Atallah, Timothy C. Burn, William Sun, Victor Sandor, Jason Gotlib	61
7	Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study 2013 ·Leukemia Research ·Ruben A. Mesa, Alan L. Shields, (unknown), Susan Erickson‐Viitanen, William Sun, Nicholas J. Sarlis, Victor Sandor, Richard S. Levy, Srđan Verstovšek	27
8	Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience 2013 ·Blood ·Ruben A. Mesa, Rami S. Komrokji, William Sun, Victor Sandor, Srđan Verstovšek	4
9	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 2013 ·Cancer ·Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Peter J. Rosen, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Paola Guglielmelli, Chiara Elena, Shui He, Nancy Contel, Bijoyesh Mookerjee, Victor Sandor, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi	131
10	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes 2013 ·OncoTargets and Therapy ·Srđan Verstovšek, Jason Gotlib, Vikas Gupta, Ehab Atallah, (unknown), Alfonso Quintás‐Cardama, William Sun, (unknown), Victor Sandor, Richard Levy, Hagop M. Kantarjian, Ruben A. Mesa	46
11	Management of Cytopenias With Ruxolitinib Treatment in Patients With Myelofibrosis 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Srđan Verstovšek, Alfonso Quintás‐Cardama, Ruben A. Mesa, Vikas Gupta, John Mascarenhas, Ehab Atallah, William Sun, Victor Sandor, Nicholas J. Sarlis, Jason Gotlib	1
12	Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts 2012 ·Blood ·Moshe Talpaz, Ronald Paquette, Lawrence B. Afrin, Solomon I. Hamburg, Katarzyna Jamieson, Howard R. Terebelo, (unknown), Roger M. Lyons, Ramón V. Tiu, Elliott F. Winton, (unknown), Olatoyosi Odenike, Wei Peng, Victor Sandor, (unknown), (unknown), Lance Leopold, Richard S. Levy, Hagop M. Kantarjian, Srđan Verstovšek	10
13	Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I 2012 ·Blood ·Ruben A. Mesa, Srđan Verstovšek, Vikas Gupta, John Mascarenhas, Ehab Atallah, William Sun, Victor Sandor, Jason Gotlib	18
14	Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report 2001 ·Blood ·Richard Piekarz, Robert W. Robey, Victor Sandor, Susan Bakke, Wyndham H. Wilson, Laila Dahmoush, (unknown), Maria L. Turner, Rosemary M. Altemus, Susan E. Bates	367
15	FR901228 causes mitotic arrest but does not alter microtubule polymerization 2000 ·Anti-Cancer Drugs ·Victor Sandor, A R Robbins, Robert W. Robey, Timothy G. Myers, Edward A. Sausville, Susan E. Bates, Dan L. Sackett	34
16	Future perspectives for the development of P-glycoprotein modulators 1998 ·Drug Resistance Updates ·Victor Sandor, Tito Fojo, Susan E. Bates	50
17	The Role of MDR-1 in Refractory Lymphoma 1997 ·Leukemia & lymphoma ·Victor Sandor, Wyndham H. Wilson, Tito Fojo, Susan E. Bates	21
18	Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay 1997 ·Blood ·Zhirong Zhan, Victor Sandor, Érick Gamelin, Joanna Regis, Bruce Dickstein, Wyndham H. Wilson, Antonio Tito Fojo, Susan E. Bates	4
19	Quantitation of the diastereoisomers of in human plasma: a validated assay by capillary electrophoresis 1995 ·Journal of Chromatography B Biomedical Sciences and Applications ·Victor Sandor, (unknown), Gerald Batist, Irving W. Wainer, David K. Lloyd	16
20	Human antiglioma monoclonal antibodies from patients with astrocytic tumors 1992 ·Journal of neurosurgery ·(unknown), (unknown), (unknown), (unknown), Delbert R. Dorscheid, Victor Sandor, Jean‐Guy Villemure, Gerald B. Price	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact